Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
A deal with Jacobio is worth $100m up front.
Studies presented at ASH show this to be true only up to a point.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
Pfizer reveals the discontinuation of PF-08046044.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
The company will try to get the Komzifti QTc prolongation warning removed.
